Vectibix panitumumab
Drug Class
EGFR antagonist monoclonal antibodyEGFR 拮抗性单克隆抗体
Mechanism
Binds specifically to EGFR, blocking ligand-induced receptor phosphorylation and downstream signaling cascades.特异性结合表皮生长因子受体（EGFR），阻断配体结合导致的受体自身磷酸化及下游信号通路的级联活化。
Approved Indication
Wild-type RAS metastatic colorectal cancer as first-line therapy (in combination with FOLFOX) or monotherapy after disease progression, per its FDA approval.根据美国FDA批准，适用于野生型RAS的转移性结直肠癌：作为一线治疗（联合FOLFOX）或在疾病进展后作为单药治疗。
What This Means For Patients
Vectibix is a targeted monoclonal antibody for patients with advanced colorectal cancer that does not have RAS mutations (wild-type). It blocks growth signals from the EGFR receptor and is available for patient access in Hainan Lecheng.Vectibix是一种针对没有RAS突变（野生型）的晚期结直肠癌患者的单克隆抗体靶向药物。它通过阻断EGFR受体介导的生长信号发挥作用，可在海南乐城先行区特许申请。
Regulatory Approvals
- FDA — approved (2006) — label
Pivotal Clinical Evidence
- PRIME — Douillard et al., J Clin Oncol 2010 (NCT00371813) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.